Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Kidney (Renal) Cancer

11 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Diagnostic

    VICCURO15104

    02/24/2017

    Contrast-enhanced Ultrasound for Complex Kidney Lesion Diagnosis in Patients with CKD (CEUS CKD)

    Treatment

    VICCURO16101

    08/10/2017

    A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination with Nivolumab in Patients with Clear Cell Renal Cell Carcinoma and Other Solid Tumors

    Treatment

    VICCMD1705

    06/12/2017

    A Phase 1B Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered with Ipilumumab, Interferon-Alpha or other Immune Modulating Therapies in Patients with Locally Advanced Metastatic Solid Tumors

    Treatment

    ECOGUROEA8143

    06/09/2017

    PHIII Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy.

    Treatment

    VICCURO16120

    05/15/2017

    A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Of Atezolizumab (Anti−PD-L1 Antibody) As Adjuvant Therapy In Patients With Renal Cell Carcinoma At High Risk Of Developing Metastasis Following Nephrectomy

    Treatment

    VICCURO1653

    03/02/2017

    A Phase 3, Multinational, Randomized, Open-Label, Parallel-Arm Study of AVELUMAB (MSB0010718C) in Combination with AXITINIB (INLYTA?) versus SUNITINIB (SUTENT?) Monotherapy in the First-Line Treatment of Patients with Advanced Renal Cell Carcinoma

    Treatment

    VICCPHI1676

    11/04/2016

    A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects with Advanced or Metastatic Solid Tumors

    Treatment

    VICCPHI1634

    08/30/2016

    A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01876 in Subjects with Advanced or Metastatic Solid Tumors

    Treatment

    VICCURO15127

    06/01/2016

    A Randomized Phase 2 Trial of AXITINIB and TRC105 versus AXITINIB Alone (Including a Lead-In Phase 1B Dose-Escalation Portion) in Patients with Advanced or Metastatic Renal Cell Carcinoma

    Treatment

    VICCGI15126

    05/03/2016

    A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

    Treatment

    VICCPHI1588

    11/27/2015

    A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors


    Print this page for your doctor